Skip to Content
8

CVS Health

  • Previous Rank7
  • Revenues ($M)$194,579.0
  • Revenue Percent Change5.3%
  • Profits ($M)$-594.0
  • Profits Percent Change-109.0%
  • Assets ($M)$196,456.0
  • Employees295,000

It was a big year for ever-bigger CVS Health, which notched a 5% increase in annual revenue, to $195 billion, as it closed its $70 billion acquisition of insurer Aetna. The Rhode Island retailer saw particular strength in its pharmacy business—thanks to more network claims and increased prescription volume—even as downward price pressure continued. But all eyes remain on Aetna, and so far, it’s tough sledding. An underwhelming February forecast, and acknowledgment that CVS would have to invest in Aetna as much as it expected to save in the deal, disappointed investors and led to its share price dropping 20% to below $55. Can CVS cure what ails it? That depends in part on what happens in Washington. In May, CEO Larry Merlo joined industry peers in criticizing proposed “Medicare for All” legislation that would eliminate private insurers and disrupt the American health care system.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
Larry J. Merlo
CEO Title
President, Chief Executive Officer & Director
Sector
Health Care
Industry
Health Care: Pharmacy and Other Services
HQ Location
Woonsocket, R.I.
Websitehttp://www.cvshealth.com
Years on Fortune 500 List26
Employees295,000
Acquired Aetna (2017 rank: 49), Nov. 28, 2018.

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$194,579.05.3%
Profits ($M)$-594.0-109.0%
Assets ($M)$196,456.0-
Total Stockholder Equity ($M)$58,225.0-

Profit Ratios

Profit as % of Revenues-0.3%
Profits as % of Assets-0.3%
Profits as % of Stockholder Equity-1.0%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)-0.57
EPS % Change (from 2017)-108.9%
EPS % Change (5 year annual rate)-
EPS % Change (10 year annual rate)-

Total Return

Total Return to Investors (2018)-7.0%
Total Return to Investors (5 year, annualized)0.3%
Total Return to Investors (10 year, annualized)10.4%